Sanja Dacic, MD, PhD
Professor of PathologyCards
About
Research
Publications
2026
Experience of the United States-Canadian Mesothelioma Reference Panel 1985-2026: Historical Review and New Developments in Mesothelial Pathology.
Churg A, Attanoos R, Beasley M, Butnor K, Chirieac L, Dacic S, Galateau-Salle F, Pavlisko E, Roden A, Roggli V, Sporn T, Tazelaar H, Travis W, Hung Y. Experience of the United States-Canadian Mesothelioma Reference Panel 1985-2026: Historical Review and New Developments in Mesothelial Pathology. Archives Of Pathology & Laboratory Medicine 2026 PMID: 42603711, DOI: 10.5858/arpa.2026-0006-ra.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsLung Cancer Biomarker Testing
Bittar H, Dacic S. Lung Cancer Biomarker Testing. The Cancer Journal 2026, 32: e0839. PMID: 42497395, DOI: 10.1097/ppo.0000000000000839.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsRadiographic tumor regression as a predictor for pathologic response after neoadjuvant therapy for non–small cell lung cancer
Bader J, Ermer T, de Santis W, Ragoowansi H, Kramer R, Tremblay E, Resio B, Boffa D, Blasberg J, Bader A, Dacic S, Woodard G. Radiographic tumor regression as a predictor for pathologic response after neoadjuvant therapy for non–small cell lung cancer. JTCVS Open 2026, 32: 101831. PMID: 42604290, PMCID: PMC13477020, DOI: 10.1016/j.xjon.2026.101831.Peer-Reviewed Original ResearchCEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma
Bader J, de Santis W, Kane E, Jaiswal A, Cho C, Kidacki M, Chen L, Dacic S, Woodard G. CEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma. Translational Lung Cancer Research 2026, 15: 131-131. PMID: 42291360, PMCID: PMC13263804, DOI: 10.21037/tlcr-2026-1-0102.Peer-Reviewed Original ResearchUpdate on Pleural Epithelioid Mesothelioma: New Insights for Diagnosis and Patient Management
Sallé F, Beasley M, Brcic L, Cooper W, Dacic S, de Perrot M, Tsao M, Klebe S, Churg A, Mansfield A, Baas P. Update on Pleural Epithelioid Mesothelioma: New Insights for Diagnosis and Patient Management. Journal Of Thoracic Oncology 2026, 21: 103720. PMID: 41962769, DOI: 10.1016/j.jtho.2026.103720.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMolecular Pathology of Lung Cancer
Lingard A, Dacic S. Molecular Pathology of Lung Cancer. Surgical Pathology Clinics 2026, 19: 275-284. PMID: 42091274, DOI: 10.1016/j.path.2026.01.003.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2025
MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype
Burns T, Dacic S, Chakka A, Miller E, Velez M, Somasundaram A, Bhattacharya S, Gaither-Davis A, Devadassan P, Jin J, Kumar V, Pennathur A, Xiu J, Oberley M, Glantz M, Aulakh S, Chandran U, Bao R, Tatsuoka C, Stabile L. MET alterations are enriched in lung adenocarcinoma brain metastases, defining a distinct biologic subtype. Journal Of Clinical Investigation 2025, 136: e194708. PMID: 41411048, PMCID: PMC12904726, DOI: 10.1172/jci194708.Peer-Reviewed Original ResearchTROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer
Jones D, Opitz I, Harpole D, Yanagawa J, Lim E, Tsutani Y, Tan D, Dacic S, Ganti A, Bodla S, Batig A, Lyfar P, Forcina A, Felip E. TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer. Journal Of Thoracic And Cardiovascular Surgery 2025, 171: 1-9. PMID: 40976544, PMCID: PMC12536336, DOI: 10.1016/j.jtcvs.2025.09.017.Peer-Reviewed Original ResearchAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCarcinoma, Non-Small-Cell LungChemotherapy, AdjuvantCirculating Tumor DNAClinical Trials, Phase III as TopicHumansImmunoconjugatesLung NeoplasmsMulticenter Studies as TopicNeoplasm StagingRandomized Controlled Trials as TopicNeoadjuvant Therapy and Lung Cancer: Role of Pathologists.
Dacic S. Neoadjuvant Therapy and Lung Cancer: Role of Pathologists. Archives Of Pathology & Laboratory Medicine 2025, 149: e78-e81. PMID: 39448058, DOI: 10.5858/arpa.2024-0203-ra.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsRandomized phase II clinical trial of sulforaphane in former smokers at high risk for lung cancer
Yuan J, Kensler T, Dacic S, Hartman D, Wang R, Balogh P, Sufka P, Turner M, Fuhrer K, Seigh L, Pham Y, Adams-Haduch J, Valacchi G, Singh S, Herman J, Wilson D. Randomized phase II clinical trial of sulforaphane in former smokers at high risk for lung cancer. Cancer Prevention Research 2025, 18: 335-345. PMID: 40041932, PMCID: PMC13321263, DOI: 10.1158/1940-6207.capr-24-0386.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News
News
- May 06, 2026Source: Lung Cancer News Today (with Sanja Dacic, MD, PhD)
Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer
- March 24, 2026
AI in Cancer Workshop: Advancing Precision Medicine through Interdisciplinary Innovation
- March 17, 2026
Yale Pathology Will Have Strong Presence at USCAP 2026
- September 08, 2025Source: OncoDaily
Dr. Sanja Dacic Awarded the 2025 Mary J. Matthews Pathology/Translational Research Award
Get In Touch
Contacts
Email
Locations
Yale New Haven Hospital
Academic Office
20 York Street, Rm EP2-631
New Haven, CT 06510